Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs, as well as shares acquired through the company’s employee stock purchase plan. For deeper insight into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available at InvestingPro. For deeper insight into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available at InvestingPro.
Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs, as well as shares acquired through the company’s employee stock purchase plan. For deeper insight into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available at InvestingPro.
Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs, as well as shares acquired through the company’s employee stock purchase plan.
In other recent news, Liquidia Corporation reported an increase in revenue for the third quarter to $4.4 million, up from $3.7 million in the same quarter last year. The company, however, reported a net loss of $23.2 million. The corporation is preparing for the potential launch of its inhaled treatment YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease after the exclusivity of TYVASO DPI expires in May 2025. Liquidia is also advancing the development of its next-generation product L606, with a pivotal study that should to begin in the first half of 2025. In addition, the company expanded its partnership with Pharmos to develop next-generation nebulizers. These are recent developments that highlight the company’s continued efforts to innovate in the healthcare space. Note that the company’s financial health and strategic partnerships indicate a strong approach to meeting the needs of patients and healthcare providers.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
